BBTC (22)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE suspends trading in commercial papers of 13 companies due to redemption with record dates set for February 13 and 16, 2026. | |||||||||||||||
BSE suspends trading in commercial papers of 13 companies due to redemption with record dates set for February 13 and 16, 2026.
| |||||||||||||||
BSE suspends trading in commercial paper of 13 companies due to record dates fixed for redemption purposes effective February 13 and 16, … | |||||||||||||||
BSE suspends trading in commercial paper of 13 companies due to record dates fixed for redemption purposes effective February 13 and 16, 2026.
| |||||||||||||||
NSE updates the list of securities eligible for Securities Lending and Borrowing Scheme (SLBS), comprising 214+ stocks across various … | |||||||||||||||
NSE updates the list of securities eligible for Securities Lending and Borrowing Scheme (SLBS), comprising 214+ stocks across various sectors. | |||||||||||||||
NSE Clearing publishes the revised list of 178+ securities eligible for transactions in the Securities Lending & Borrowing Scheme (SLBS) for … | |||||||||||||||
NSE Clearing publishes the revised list of 178+ securities eligible for transactions in the Securities Lending & Borrowing Scheme (SLBS) for January 2026. | |||||||||||||||
BSE surveillance requested clarifications from Solara Active Pharma Sciences, Bombay Burmah Trading Corporation, and Capital India Finance … | |||||||||||||||
BSE surveillance requested clarifications from Solara Active Pharma Sciences, Bombay Burmah Trading Corporation, and Capital India Finance regarding significant increase in trading volumes. All companies confirmed compliance with disclosure requirements and stated no price-sensitive information was withheld.
| |||||||||||||||
Three companies (Solara Active Pharma Sciences, Bombay Burmah Trading Corporation, and Capital India Finance) clarified to BSE that they … | |||||||||||||||
Three companies (Solara Active Pharma Sciences, Bombay Burmah Trading Corporation, and Capital India Finance) clarified to BSE that they have disclosed all material information and have no undisclosed price-sensitive information regarding recent volume spikes in their securities.
| |||||||||||||||
BSE announces listing of 1100 Commercial Papers of Rs.5 lakh each issued by The Bombay Burmah Trading Corporation Ltd. on private placement … | |||||||||||||||
BSE announces listing of 1100 Commercial Papers of Rs.5 lakh each issued by The Bombay Burmah Trading Corporation Ltd. on private placement basis, rated CRISIL A1+.
| |||||||||||||||
BSE lists 1100 Commercial Papers of Rs. 5 lakh each issued by The Bombay Burmah Trading Corporation Ltd. on private placement basis, rated … | |||||||||||||||
BSE lists 1100 Commercial Papers of Rs. 5 lakh each issued by The Bombay Burmah Trading Corporation Ltd. on private placement basis, rated CRISIL A1+.
| |||||||||||||||
BSE announces listing of Rs. 250 crore Commercial Paper issued by The Bombay Burmah Trading Corporation Ltd. with tenure of 1 year, rated … | |||||||||||||||
BSE announces listing of Rs. 250 crore Commercial Paper issued by The Bombay Burmah Trading Corporation Ltd. with tenure of 1 year, rated IND A1+.
| |||||||||||||||
BSE announces an amendment in the corporate name of Bombay Burmah Trading Corporation Ltd (Scrip code: 501425). | |||||||||||||||
BSE announces an amendment in the corporate name of Bombay Burmah Trading Corporation Ltd (Scrip code: 501425).
| |||||||||||||||